Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India.
Int Immunopharmacol. 2023 Dec;125(Pt A):111095. doi: 10.1016/j.intimp.2023.111095. Epub 2023 Oct 23.
Although the concept of using the patient's immune system to combat cancer has been around for a while, it is only in recent times that substantial progress has been achieved in this field. Over the last ten years, there has been a significant advancement in the treatment of cancer through immune checkpoint blockade. This treatment has been approved for multiple types of tumors. Another approach to modifying the immune system to detect tumor cells and fight them off is adaptive cell therapy (ACT). This therapy involves using T cells that have been modified with either T cell receptors (TCR) or chimeric antigen receptors (CAR) to target the tumor cells. ACT has demonstrated encouraging outcomes in different types of tumors, and clinical trials are currently underway worldwide to enhance this form of treatment. This review focuses on the advancements that have been made in ACT from preclinical to clinical settings till now.
虽然利用患者的免疫系统来对抗癌症的概念已经存在了一段时间，但直到最近，该领域才取得了实质性的进展。在过去的十年中，通过免疫检查点阻断在癌症治疗方面取得了重大进展。这种治疗方法已经批准用于多种类型的肿瘤。另一种修饰免疫系统以检测肿瘤细胞并将其消灭的方法是适应性细胞疗法 (ACT)。这种疗法涉及使用经过修饰的 T 细胞，这些 T 细胞要么带有 T 细胞受体 (TCR)，要么带有嵌合抗原受体 (CAR)，以靶向肿瘤细胞。ACT 在不同类型的肿瘤中显示出令人鼓舞的结果，目前全球范围内正在进行临床试验以增强这种治疗形式。这篇综述重点介绍了从临床前到临床环境中 ACT 取得的进展。
